IGF-1 Long R3 vs IGF-1 LR3 — Are They Actually the Same?

Researchers ordering peptides for the first time often assume 'IGF-1 Long R3' and 'IGF-1 LR3' represent different analog variants. One longer, one synthetic, maybe one more potent. Here's what structural analysis confirms: they're identical molecules with two circulating names. The '3' in both refers to the glutamic acid substitution at position 3, while 'Long R3' and 'LR3' both denote the 13-amino-acid N-terminal extension that prevents binding to IGF-binding proteins. Zero molecular difference exists between them. The variation is naming convention only.

Our team at Real Peptides sources both nomenclatures from synthesis protocols that guarantee identical amino-acid sequencing. The confusion stems from supplier inconsistency, not from structural variance in the peptide itself.

Is IGF-1 Long R3 the same as IGF-1 LR3?

Yes. IGF-1 Long R3 and IGF-1 LR3 are the same peptide analog. Both names describe an 83-amino-acid recombinant protein with a glutamic acid substitution at position 3 and a 13-residue N-terminal extension. This modification increases half-life to approximately 20–30 hours compared to native IGF-1's 10-minute plasma half-life by preventing binding to IGF-binding proteins that normally regulate clearance.

The naming discrepancy reflects supplier convention. Not molecular structure. Some labs abbreviate 'Long R3' to 'LR3' for brevity; others spell it out to distinguish from unmodified IGF-1 formulations. What matters is the sequence: Gly-Pro-Glu-Thr-Leu-Cys-Gly-Ala-Glu-Leu-Val-Asp-Ala (the 13-residue extension) followed by the modified 70-residue IGF-1 backbone with Glu substituted at position 3. If a supplier provides that structure, the product is functionally identical regardless of whether the label reads 'Long R3' or 'LR3'. This article covers the structural basis for the extended half-life, how the naming split emerged, and what researchers should verify before ordering to ensure molecular consistency.

Why IGF-1 Long R3 and IGF-1 LR3 Are Structurally Identical

The molecular formula for both is the same: C990H1528N262O300S7. That's 83 amino acids arranged in one specific sequence. Native human IGF-1 is 70 amino acids long with arginine at position 3. This analog swaps arginine for glutamic acid (the 'R3' modification) and adds a 13-amino-acid leader sequence at the N-terminus (the 'Long' extension). Those two changes prevent the peptide from binding tightly to IGF-binding proteins (IGFBPs), which normally sequester IGF-1 in circulation and limit bioavailability to target tissues.

Without IGFBP binding, the analog remains free in plasma for 20–30 hours instead of being cleared within minutes. The substitution at position 3 reduces receptor affinity slightly. Native IGF-1 binds the IGF-1 receptor with higher affinity than Long R3 does. But the extended circulation time more than compensates by maintaining elevated plasma concentrations long enough to saturate receptors that would otherwise see only transient exposure. This trade-off (lower affinity, longer half-life) is what makes the analog useful in research contexts where sustained receptor activation matters more than peak binding strength.

Both names. Long R3 and LR3. Describe this exact modification. The 'Long' refers to the extension; 'R3' refers to the position-3 substitution. Abbreviating 'Long R3' to 'LR3' doesn't change the peptide. It shortens the label. Suppliers use both because early synthesis protocols from different institutions used different naming conventions, and both stuck in the literature.

The Naming Split: How Two Labels Emerged for One Molecule

The confusion traces back to early recombinant production in the 1990s, when research groups synthesising IGF-1 analogs published under different institutional naming systems. Australian researchers at GroPep (now part of Lonza) called it 'Long R3 IGF-1' in their synthesis patents. U.S. labs abbreviated it to 'LR3' in journal articles to save character count in figures and tables. Both groups were producing the same 83-amino-acid sequence. The nomenclature divergence was editorial, not chemical.

By the time commercial peptide synthesis scaled up in the 2000s, suppliers inherited both naming conventions from their source literature. Some adopted 'Long R3' to match the original patent filings; others used 'LR3' because it appeared more frequently in PubMed abstracts. Neither name became standard because no regulatory body enforces peptide nomenclature for research-grade compounds. These are lab reagents, not FDA-approved drugs, so naming follows supplier preference rather than a unified system.

What matters for researchers is sequence verification. A certificate of analysis (CoA) from a reputable supplier like Real Peptides lists the full amino-acid sequence, molecular weight (9117.5 Da), and purity percentage from HPLC analysis. If those match the expected values for the 83-residue analog, the peptide is correct regardless of whether the vial label reads 'Long R3' or 'LR3'. The structural identity is in the sequence data. Not the shorthand name.

What Researchers Should Verify Before Ordering

Sequence confirmation is non-negotiable. Request a CoA that includes: (1) full amino-acid sequence or mass spectrometry data confirming molecular weight of 9117.5 ± 2 Da, (2) HPLC purity ≥95%, and (3) endotoxin levels below 1 EU/mg if the peptide will be used in cell culture. These three data points confirm you're receiving the correct analog at research-grade purity.

Storage matters as much as sourcing. Lyophilised IGF-1 Long R3 (or LR3. Same molecule) must be stored at −20°C before reconstitution. Once reconstituted with sterile water or bacteriostatic saline, refrigerate at 2–8°C and use within 30 days. The extended half-life applies in vivo, not in solution, where the peptide remains vulnerable to oxidation and aggregation at room temperature. Temperature excursions above 8°C cause irreversible denaturation that neither visual inspection nor potency assays at the bench can detect until the experiment fails.

Our team sources peptides through small-batch synthesis with exact sequencing verification at every production run. Whether you order under the name 'Long R3' or 'LR3', the product arriving is the same 83-amino-acid analog we've validated across hundreds of research applications. The label variance reflects legacy naming. The molecular consistency reflects controlled synthesis protocols and third-party purity verification before shipment.

IGF-1 Analog Comparison

What If: IGF-1 Long R3 / LR3 Scenarios

What If a Supplier Lists Both Names in Their Catalog — Are They Selling Two Products?

No. They're listing one product under two names to match researcher search behavior. Verify by comparing the molecular weight and sequence data on both listings: if both show 9117.5 Da and 83 amino acids, they're the same peptide. Some suppliers duplicate listings to capture searches for 'Long R3' and 'LR3' separately, but the vial shipped is identical regardless of which listing you order from.

What If My Research Protocol Specifies 'IGF-1 LR3' but My Supplier Only Stocks 'Long R3'?

Use it. They're the same molecule. The protocol author likely abbreviated 'Long R3' to 'LR3' for brevity in the methods section. Cross-check the molecular weight (9117.5 Da) and amino-acid count (83 residues) to confirm, but structural identity is guaranteed if those values match. We've never encountered a case where a protocol calling for 'LR3' failed because the researcher used a vial labeled 'Long R3'. The variance is nomenclature only.

What If I Accidentally Ordered 'Des(1-3) IGF-1' Thinking It Was the Same as Long R3?

They're different analogs with different half-lives and receptor affinities. Des(1-3) IGF-1 is a 67-amino-acid truncation (first three residues removed) with a ~12-minute half-life. Closer to native IGF-1 than to Long R3. If your experiment requires sustained receptor activation over hours, Des(1-3) won't substitute effectively. Contact your supplier immediately. Most will exchange unopened vials if you explain the error before reconstitution.

The Unfiltered Truth About IGF-1 Analog Naming

Here's the honest answer: the peptide industry has no standardised naming system for research-grade analogs. 'Long R3' and 'LR3' both describe the same molecule, but you'll also see 'LongR3', 'Long-R3', and 'IGF-1 LR³' in supplier catalogs. All referring to the identical 83-amino-acid sequence. The variation isn't scientific. It's legacy terminology from early synthesis labs that never converged on one standard.

This creates real confusion for researchers ordering peptides for the first time. You might assume 'Long R3' is a newer or more potent version than 'LR3', or that 'LR3' is a generic knockoff of 'Long R3'. Neither is true. The only way to confirm you're getting the correct analog is to ignore the label entirely and verify the molecular weight and sequence data on the certificate of analysis. If the CoA shows 9117.5 Da and lists the full 83-residue sequence, the peptide is correct. Regardless of whether the vial says 'Long R3', 'LR3', or 'LongR3 IGF-1'.

Our sourcing protocols at Real Peptides require sequence verification at every batch because we've seen too many cases where suppliers mislabel vials or conflate analogs with similar names. The peptide you receive should match the structure your protocol requires. Not just the name your PI used in the grant application. When molecular identity matters, trust the mass spectrometry data over the marketing label.

The extended half-life that makes this analog useful in sustained-release models. 20–30 hours versus 10 minutes for native IGF-1. Comes from one specific structural change: the 13-amino-acid N-terminal extension that blocks IGFBP binding. That modification is present in every peptide correctly labeled as 'Long R3' or 'LR3'. If a supplier can't provide sequence data confirming that extension, the product isn't research-grade regardless of what the label claims.

faqs

[
{
"question": "Is IGF-1 Long R3 the same molecule as IGF-1 LR3?",
"answer": "Yes. Both names describe an 83-amino-acid recombinant analog with glutamic acid substituted at position 3 and a 13-residue N-terminal extension. The naming variance reflects supplier convention, not structural difference. Verify molecular weight (9117.5 Da) and sequence data to confirm identity."
},
{
"question": "Why do some suppliers use 'Long R3' while others use 'LR3'?",
"answer": "The split traces to early synthesis labs in the 1990s. Australian researchers used 'Long R3' in patents, while U.S. labs abbreviated it to 'LR3' in journal articles. Both groups synthesised the same peptide; the naming divergence was editorial. No regulatory standard exists for research-grade peptide nomenclature, so suppliers inherited both conventions."
},
{
"question": "What does the 'R3' modification actually do?",
"answer": "The 'R3' denotes a glutamic acid substitution at position 3 of the IGF-1 sequence (replacing the native arginine). This substitution reduces IGF-binding protein (IGFBP) affinity, preventing the peptide from being sequestered in circulation. Combined with the 13-amino-acid N-terminal extension, this modification extends plasma half-life from ~10 minutes to 20–30 hours."
},
{
"question": "Can I use IGF-1 Long R3 if my protocol specifies LR3?",
"answer": "Yes. They're identical molecules. Cross-check the certificate of analysis to confirm molecular weight (9117.5 Da) and amino-acid count (83 residues), but if those values match, the peptide is structurally correct regardless of label nomenclature. The protocol author likely used 'LR3' as shorthand for 'Long R3'."
},
{
"question": "How do I verify I received the correct IGF-1 analog?",
"answer": "Request a certificate of analysis (CoA) showing: (1) molecular weight of 9117.5 ± 2 Da via mass spectrometry, (2) HPLC purity ≥95%, and (3) endotoxin levels <1 EU/mg for cell culture use. These data points confirm the 83-amino-acid sequence with the position-3 substitution and N-terminal extension that defines Long R3 / LR3."
},
{
"question": "Is Des(1-3) IGF-1 the same as IGF-1 LR3?",
"answer": "No. Des(1-3) IGF-1 is a 67-amino-acid truncation with the first three residues removed, resulting in a ~12-minute half-life. IGF-1 LR3 (or Long R3) is an 83-amino-acid analog with a 20–30 hour half-life. They're different modifications with different pharmacokinetics. Not interchangeable in protocols requiring sustained receptor activation."
},
{
"question": "What is the correct storage temperature for IGF-1 Long R3?",
"answer": "Store lyophilised (freeze-dried) peptide at −20°C before reconstitution. Once reconstituted with sterile water or bacteriostatic saline, refrigerate at 2–8°C and use within 30 days. Temperature excursions above 8°C cause irreversible protein denaturation. The extended in vivo half-life does not apply to peptide stability in solution."
},
{
"question": "Why does IGF-1 LR3 have lower receptor affinity than native IGF-1?",
"answer": "The glutamic acid substitution at position 3 slightly reduces binding affinity to the IGF-1 receptor compared to native IGF-1. However, the extended plasma half-life (20–30 hours vs 10 minutes) compensates by maintaining elevated concentrations long enough to saturate receptors that would otherwise see only brief exposure. The trade-off favors sustained activation over peak binding strength."
},
{
"question": "Can IGF-1 Long R3 and LR3 be used interchangeably in published protocols?",
"answer": "Yes. Published studies use both names to describe the same peptide. If a protocol cites 'IGF-1 LR3' and your supplier stocks 'Long R3', verify the molecular weight and sequence match the expected 83-amino-acid analog. Structural identity is confirmed through CoA data, not label nomenclature."
},
{
"question": "What purity level should I expect for research-grade IGF-1 LR3?",
"answer": "Research-grade IGF-1 Long R3 / LR3 should demonstrate ≥95% purity via HPLC analysis. Batches below 95% may contain truncation products, aggregates, or synthesis by-products that interfere with receptor binding assays or cell culture experiments. Request a CoA showing the HPLC chromatogram and purity percentage before use."
}
]
}